HER2-POSITIVE BREAST CANCER

This early-stage study is testing the safety of combining a targeted cancer drug (Trastuzumab Deruxtecan) with precise radiation therapy for people with HER2-positive breast cancer that has spread to the brain. The goal is to see if this combination can better control the cancer …

This study is testing whether adding a drug called neratinib to a standard treatment (Trastuzumab Deruxtecan) works better for controlling advanced HER2-positive breast cancer that has spread to the brain. It will involve 202 women in China who will receive one of the two treatme…

This study is testing whether a new drug called SHR-A1811 works better and is safer than the current standard treatment for people with advanced HER2-positive breast cancer whose cancer stopped responding to their first targeted therapy. About 100 adults with this specific type o…

This study is testing whether adding a drug called pyrotinib to two standard medications (trastuzumab and pertuzumab) can better control advanced HER2-positive breast cancer after initial chemotherapy. It will follow 42 patients in a real-world setting to see if this combination …

This study is testing whether a new drug called RC48, when combined with standard chemotherapy, works better than current standard treatments for advanced HER2-positive breast cancer. It's for people whose cancer has continued to grow despite previous treatment with a specific ty…

This study is testing a new type of 'theranostic' drug that first acts like a medical dye to locate cancer in the brain and then delivers targeted radiation to treat it. It is for adults with solid tumors, including HER2-positive breast cancer, that have spread to the brain and a…

This study is testing two different maintenance drug combinations to help control advanced HER2-positive breast cancer after initial treatment. Researchers want to see which approach works better at keeping the cancer from progressing, based on whether patients also have hormone-…

This study is testing whether some breast cancer patients who respond exceptionally well to chemotherapy might be able to avoid surgery. It will enroll 84 people with HER2-positive or triple-negative breast cancer. Patients who show a complete response to chemo will be monitored …

This study is testing whether a new experimental drug called RO7771950 works better than the current standard treatment (tucatinib) for advanced HER2-positive breast cancer that has spread or is hard to treat. Both drugs are given with two other cancer medications (trastuzumab an…

This study tests whether Herombopag tablets can prevent low platelet counts (thrombocytopenia) in HER2-positive breast cancer patients receiving T-DM1 therapy. Low platelets are a common side effect that can cause bleeding risks and force treatment delays. The research will invol…